Clinical and Economic Outcomes of Intravenous Brivaracetam Compared With Levetiracetam for the Treatment of Seizures in United States Hospitals

Clinical and Economic Outcomes of Intravenous Brivaracetam Compared With Levetiracetam for the Treatment of Seizures in United States Hospitals

Background: Seizures are common among hospitalized patients. Levetiracetam (LEV), a synaptic vesicle protein 2A (SV2A) ligand, is a common intravenous (IV) anti-seizure medication option in hospitals. Brivaracetam (BRV), a selective SV2A ligand for treatment of focal seizures in patients ≥16 years,...

Full description

Bibliographic Details
Main Authors: Silky Beaty, Ning A. Rosenthal, Julie Gayle, Prashant Dongre, Kristen Ricchetti-Masterson
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-11-01
Series:Frontiers in Neurology
Subjects:
intravenous antiseizure medication
SV2A ligand
seizure
hospital
effectiveness
cost
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2021.760855/full

Internet

https://www.frontiersin.org/articles/10.3389/fneur.2021.760855/full

Similar Items